Oral Insulin AFREZZA Successful at Controlling Blood Sugar Levels in Type 1 Diabetes Patients

MannKind announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin (also combined with basal insulin), in reducing HbA1c levels in subjects with inadequately controlled type 1 diabetes. In addition, patients treated with AFREZZA had statistically significant lower rates of hypoglycemia, post-prandial glucose levels when measured at 30, 60, 90 and 120 minutes, and fasting blood glucose levels when compared to subcutaneously injected insulin lispro.

ASweetLife Team

Novo Nordisk Drops Oral Insulin Development Projects
According to an article published on Seeking Alpha, Novo Nordisk has decided to make some significant changes in its drug development strategy as a result of the 'current payment atmosphere’ in…
Inhaled Insulin for Diabetes: Is Afrezza Worth the Risks?
Will I prescribe Afrezza for people with diabetes? Not a lot, and not for past or present smokers, and not for people with any breathing problems (or heart issues that…
FDA Advisory Committee Recommends Approval of…
The U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 1 to recommend that Afrezza (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA
FDA Approves Afrezza Rapid-Acting Inhaled Insulin
The U.S. FDA approved Mannkind Corporation's Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin, to improve glycemic control in adults with diabetes mellitus. Afrezza is administered at the beginning…
Sanofi Licenses Afrezza Inhaled Insulin from MannKind
Sanofi and MannKind Corporation have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin